Jim Broderick, M.D.
Partner
Jim is a Partner on the Morgenthaler Life Sciences Team and invests in companies developing innovative therapeutic products in the biotech and medical device industries.
Jim is a cofounder and investor in Ra Pharmaceuticals, a biotech platform company developing orally available and cell permeable biologics.
He is also the founding CEO and serves as a board member at SetPoint Medical, a company developing implantable medical devices to treat inflammatory diseases. In addition, Jim is a co-founder and serves as board member at Promedior Pharmaceuticals, a Malvern Pennsylvania-based company developing drugs to prevent and treat fibrotic diseases such as end stage renal disease, liver cirrhosis, and pulmonary fibrosis. He is an investor and board member of several other novel biotech and medical device companies, including Cardiopolymers, OncoMed Pharmaceuticals, Spine Wave, and Trellis Bioscience. He also previously served as a director at Bayhill Therapeutics and NexTag.
Jim opened Morgenthaler’s Boston Office in 2005 after spending several years in Silicon Valley. Trained as a physician and an engineer, Jim is a graduate of MIT (Bachelors in Mechanical Engineering) and University of Massachusetts (Doctor of Medicine). Jim was a member of the Kauffman Fellows Program, a two–year educational fellowship sponsored by the Kauffman Center for Entrepreneurial Leadership designed to train future venture capitalists and leaders of high growth companies. Jim had previously worked as a consultant at Mercer Management Consulting, and as a resident at Duke University Medical Center.
Education:
MIT (B.S. Mechanical Engineering) University of Massachusetts Medical School (M.D.)
Board Seats:
Current:
- OncoMed Pharmaceuticals
- Promedior Pharmaceuticals
- Ra Pharmaceuticals
- Setpoint Medical
- Spine Wave
- Symphony Medical
- Trellis Bioscience
Previous:
Portfolio News:
